Nature Medicine, Published online: 18 October 2025; doi:10.1038/s41591-025-04032-8
As presented at the ASCO 2025 Annual Meeting and the ESMO Congress 2025: In RELATIVITY-098, treatment of patients with stage III/IV resected melanoma with nivolumab and relatlimab compared to nivolumab alone did not significantly change recurrence-free survival, with correlative data pointing to the absence of tumor-infiltrating LAG3+ T cells as a potential reason.- October 18, 2025
- 0 Comment
Nature Medicine, Published online: 18 October 2025; doi:10.1038/s41591-025-04022-w
As presented at the ESMO Congress 2025: in this international, single-arm phase 2 trial, first-line treatment of patients with advanced gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma with domvanalimab (Fc-silent anti-TIGIT) and zimberelimab (anti-PD-1) plus FOLFOX (oxaliplatin, leucovorin and fluorouracil) led to encouraging objective response rates and survival outcomes, which will be validated in a phase 3 trial.- October 18, 2025
- 0 Comment
Nature Medicine, Published online: 18 October 2025; doi:10.1038/s41591-025-03979-y
As presented at the ESMO Congress 2025, in the single-arm phase 2 IKF/AIO PHERFLOT trial, the perioperative combination of FLOT chemotherapy with anti-PD-1 and anti-HER2 monoclonal antibodies led to a pathological complete response rate of 48.4% in patients with resectable HER2+ esophagogastric adenocarcinoma, meeting the prespecified co-primary endpoint.- October 18, 2025
- 0 Comment
US sales of certified organic products accelerated in 2024 with an annual growth rate of 5.2%, more than double that of the overall marketplace which grew at 2.5% in the same period. Dollar sales for organic also reached a new high of $71.6 billon in 2024, according to the 2025 Organic Market Report.
- October 16, 2025
- 0 Comment
Nature Medicine, Published online: 16 October 2025; doi:10.1038/s41591-025-03976-1
The authors explore the impact of MC4R deficiency on lipid metabolism in humans, based on two large cohorts. Findings indicate that individuals with obesity due to MC4R deficiency have lower cholesterol and triglyceride levels, as well as reduced cardiovascular risk.- October 16, 2025
- 0 Comment
Nature Medicine, Published online: 16 October 2025; doi:10.1038/s41591-025-04008-8
The latest large language model from OpenAI offers safety gains, persistent risks and the illusion of understanding.- October 16, 2025
- 0 Comment
Nature Medicine, Published online: 16 October 2025; doi:10.1038/s41591-025-03941-y
A new study provides physiological insights into the dying process, which could have substantial implications for resuscitation science, death determination and organ donation.- October 16, 2025
- 0 Comment
Nature Medicine, Published online: 16 October 2025; doi:10.1038/s41591-025-04024-8
BioCog is a brief, self-administered digital test battery that helps to accurately detect cognitive impairment in primary care patients undergoing evaluation for a possible neurodegenerative disease. When combined with blood biomarker tests, the digital test outperformed current standard-of-care assessments of Alzheimer’s disease, supporting a more precise, efficient and timely diagnosis.- October 16, 2025
- 0 Comment
Nature Medicine, Published online: 15 October 2025; doi:10.1038/s41591-025-03993-0
A randomized, controlled phase 1b trial evaluated the safety, pharmacokinetics and impact on viral kinetics of budigalimab, a PD-1 inhibitor, during analytical treatment interruption for HIV and found that it was well tolerated and resulted in delayed rebound in a subset of participants in an exploratory efficacy analysis.- October 15, 2025
- 0 Comment
Nature Medicine, Published online: 15 October 2025; doi:10.1038/s41591-025-03991-2
Germany is paving the way toward genomics-based personalized healthcare and translational research.- October 15, 2025
- 0 Comment
